Heska (NASDAQ:HSKA) Shares Down 3.3%

Heska Co. (NASDAQ:HSKA – Get Rating)’s stock price was down 3.3% during mid-day trading on Friday . The company traded as low as $83.01 and last traded at $83.17. Approximately 6,397 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 138,455 shares. The stock had previously closed at $86.03.

Wall Street Analyst Weigh In

Several research firms have recently commented on HSKA. StockNews.com assumed coverage on Heska in a research note on Wednesday, October 12th. They set a “hold” rating for the company. JPMorgan Chase & Co. reduced their target price on shares of Heska from $175.00 to $150.00 and set an “overweight” rating for the company in a research note on Monday, October 17th. Alliance Global Partners dropped their price target on shares of Heska from $155.00 to $119.00 and set a “buy” rating on the stock in a research note on Wednesday, November 9th. Morgan Stanley downgraded shares of Heska from an “equal weight” rating to an “underweight” rating and set a $58.00 price objective for the company. in a research report on Friday, January 6th. Finally, Piper Sandler dropped their target price on Heska from $170.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, November 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, Heska has an average rating of “Hold” and an average target price of $123.00.

Heska Stock Performance

The stock’s 50 day moving average price is $66.88 and its two-hundred day moving average price is $77.00. The company has a current ratio of 7.18, a quick ratio of 5.61 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $926.81 million, a price-to-earnings ratio of -54.53 and a beta of 1.40.

Heska (NASDAQ:HSKA – Get Rating) last issued its earnings results on Tuesday, November 8th. The medical research company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. The company had revenue of $61.49 million during the quarter, compared to analysts’ expectations of $69.72 million. Heska had a negative net margin of 6.26% and a positive return on equity of 0.09%. On average, analysts forecast that Heska Co. will post 0.26 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Kevin S. Wilson purchased 11,018 shares of the company’s stock in a transaction dated Friday, January 6th. The stock was acquired at an average price of $58.62 per share, for a total transaction of $645,875.16. Following the completion of the transaction, the chief executive officer now directly owns 167,072 shares in the company, valued at approximately $9,793,760.64. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Kevin S. Wilson acquired 11,018 shares of the business’s stock in a transaction that occurred on Friday, January 6th. The stock was purchased at an average cost of $58.62 per share, for a total transaction of $645,875.16. Following the transaction, the chief executive officer now directly owns 167,072 shares of the company’s stock, valued at approximately $9,793,760.64. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Kevin S. Wilson bought 3,440 shares of Heska stock in a transaction that occurred on Thursday, December 22nd. The stock was bought at an average cost of $59.64 per share, for a total transaction of $205,161.60. Following the purchase, the chief executive officer now owns 156,054 shares in the company, valued at approximately $9,307,060.56. The disclosure for this purchase can be found here. 11.00% of the stock is owned by company insiders.

Institutional Trading of Heska

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP boosted its stake in shares of Heska by 245.6% during the 3rd quarter. Quantbot Technologies LP now owns 508 shares of the medical research company’s stock worth $37,000 after purchasing an additional 361 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of Heska during the second quarter valued at approximately $39,000. Point72 Hong Kong Ltd acquired a new stake in Heska during the first quarter worth approximately $57,000. UBS Group AG grew its stake in Heska by 83.1% in the 3rd quarter. UBS Group AG now owns 1,703 shares of the medical research company’s stock worth $124,000 after acquiring an additional 773 shares during the period. Finally, Mutual of America Capital Management LLC raised its holdings in Heska by 11.7% in the 3rd quarter. Mutual of America Capital Management LLC now owns 2,024 shares of the medical research company’s stock valued at $148,000 after acquiring an additional 212 shares during the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Heska Company Profile

(Get Rating)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.